Skip to main content
PMC home page
Canadian Journal of Gastroenterology & Hepatology logoLink to Canadian Journal of Gastroenterology & Hepatology
. 2014 Sep;28(8):439–444. doi: 10.1155/2014/350179

Caesarean section to prevent transmission of hepatitis B: A meta-analysis

Matthew S Chang 1, Sravanya Gavini 1, Priscila C Andrade 2, Julia McNabb-Baltar 1,✉
PMCID: PMC4210235  PMID: 25229465

The advent of universal screening of pregnant women for hepatitis B virus (HBV) has dramatically decreased vertical transmission rates. However, for women with high viral loads or positive antigen levels, transmission remains an issue for up to one-fifth of cases. Given the global prevalence of hepatitis B infection and the health burden of its related sequelae, investigating approaches to mitigate transmission will prove to be highly valuable. This random-effects pooled meta-analysis included 10 studies that met the authors’ inclusion criteria.

Keywords: Hepatitis, Hepatitis B immune globulin, Prophylaxis, Vaccination

Abstract

BACKGROUND:

Vertical transmission of hepatitis B virus (HBV) occurs in up to 10% to 20% of births.

OBJECTIVE:

To assess whether Caesarean section, compared with vaginal delivery, prevents HBV transmission.

METHODS:

A systematic review and meta-analysis was conducted. Two investigators independently searched PubMed, EMBASE and other databases for relevant studies published between 1988 and 2013. A manual search of relevant topics and major conferences for abstracts was also conducted. Randomized trials, cohort and case-control studies assessing the effect of delivery mode on vertical transmission of HBV were included. Studies assessing antiviral therapy and patients with coinfection were excluded. The primary outcome was HBV transmission rates according to delivery method.

RESULTS:

Of the 430 studies identified, 10 were included. Caesarean section decreased the odds of HBV transmission by 38% compared with vaginal delivery (OR 0.62 [95% CI 0.40 to 0.98]; P=0.04) based on a random-effects model. Significant heterogeneity among studies was found (I2=63%; P=0.003), which was largely explained by variation in hepatitis B immune globulin (HBIG) administration. Meta-regression showed a significant linear association between the percentage of infants receiving HBIG per study and the log OR (P=0.005), with the least benefit observed in studies with 100% HBIG administration. Subgroup analysis of hepatitis B e-antigen-positive women who underwent Caesarean section did not show a significant reduction in vertical transmission.

DISCUSSION:

Caesarean section may protect against HBV transmission; however, convincing benefit could not be demonstrated due to significant study heterogeneity from variable HBIG administration, highlighting the importance of HBIG in HBV prevention.

CONCLUSION:

More high-quality studies are needed before any recommendations can be made.

Four hundred million individuals are infected with hepatitis B virus (HBV) worldwide (1), which can lead to chronic hepatitis, cirrhosis and hepatocellular carcinoma. Most chronic infections are acquired perinatally via vertical transmission from the mother (2). HBV transmission has declined dramatically with the advent of universal screening of pregnant women in conjunction with passive and active immunization using hepatitis B immune globulin (HBIG) and HBV vaccine in the neonatal period. However, transmission remains as high as 10% to 20% in cases for which the mother has high viral DNA or positive hepatitis B e antigen (HBeAg) levels (3,4).

With HIV, Caesarean section has been shown to be efficacious in reducing vertical transmission from highly contagious mothers to their infants (5). In contrast, the effect of delivery mode on HBV transmission remains controversial (6,7). Accordingly, we performed a systematic review and meta-analysis to determine whether Caesarean section, compared with vaginal delivery, prevented transmission of HBV from infected mother to infant.

METHODS

Data sources and searches

The Cochrane Collaboration methodology was applied to search PubMed, EMBASE, LILACS, BIOSIS and the Cochrane databases for articles in English, Portuguese, French or Spanish from 1988 to 2013. In addition, references of relevant articles and abstracts from major conferences were manually searched. The following search terms were used as both keywords and medical subject heading terms, where applicable, after consultation with a reference librarian (Paul Bain PhD, Harvard Medical School, Countway Library of Medicine, Boston, USA): Hepatitis B, Hepatitis B Virus, HBV, HBsAg, HBeAg, Caesarean Section, C section, “Mode of delivery”, Pregnancy, Vertical Transmission, Perinatal Transmission, mother-to-child transmission, prevention. PubMed was searched for “Hepatitis B”[Mesh] OR “Hepatitis B virus”[Mesh] OR hepatitis b[tiab] OR HBV[tiab] OR HBsAg[tiab] OR HBeAg[tiab] AND (c section*[tiab] OR Caesarean*[tiab] OR “Caesarean Section”[Mesh] OR ECS[tiab]) and EMBASE was searched for ‘hepatitis B’/exp OR ‘hepatitis b’:ti,ab OR HBV:ti,ab OR HBsAg:Ti,ab OR HBeAg:ti,ab, combined with ‘Caesarean section’/exp OR caesarean*:ti,ab OR ‘c section’:ti,ab OR ‘c sections’:ti,ab OR ecs:ti,ab. Authors were contacted when data were ambiguous or missing.

Study selection

Inclusion criteria were determined a priori among the authors. Published and in-print randomized controlled trials, cohort studies and case-control studies were included. Overlapping studies, meta-analyses, systematic reviews, case reports/series, expert opinion, editorials, duplicates and animal studies were excluded. Eligible studies evaluated infants of pregnant mothers with chronic HBV infection, defined as positive hepatitis B surface antigen (8) who underwent Caesarean section or vaginal delivery. The intervention of interest was Caesarean section and the comparator was vaginal delivery. The outcome was vertical transmission of HBV. Studies in which the primary intervention was nucleos(t)ide therapy were excluded.

Data extraction and quality assessment

Two authors performed the database search independently and compared their search results; another independent author reviewed discrepancies. Two authors independently conducted the data extraction process and disagreements were resolved by discussion between the two review authors. When agreement could not be reached, a third author acted as an arbiter. Additional data from one abstract presented at the annual European Association for the Study of the Liver conference (9) was obtained from the authors via e-mail (personal communication, Dr Sheng-Nan Lu, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan). Data extraction from articles was performed using a form that was designed a priori to include study design, source country, exclusion criteria, number of infants and rates of vertical HBV transmission stratified according to Caesarean section and vaginal delivery, percentage of mothers who were HBeAg positive (HBeAg+), percentage of mothers that had HBV DNA >106 copies/mL, percentage of infants who received HBIG and dose administered, and percentage of infants who received HBV vaccine and schedule. During the data extraction process, the following details were added to the a priori form: elective versus urgent Caesarean section and use of assist devices during vaginal delivery, such as forceps or vacuum suction. During data extraction, the meta-estimate was changed from risk ratios to ORs for all studies because one study was a case control. The final search was performed on August 11, 2013.

The methodological quality of each study was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS), which is a method for assessing the quality of nonrandomized studies in meta-analyses (10). The NOS allocates a maximum of nine stars to assess three domains: quality of study group selection, comparability of intervention and nonintervention groups, and ascertainment of the exposure and outcome.

Data synthesis and analysis

The outcome of interest was HBV transmission to the infant, defined as either hepatitis B surface antigen positive or detectable HBV DNA level. The ORs of developing HBV in infants were obtained from the studies and stratified analyses were performed according to maternal HBV DNA levels >106 copies/mL and HBeAg+ status, which are measures of high viral infectivity. Also performed was an additional subgroup analysis of elective versus urgent Caesarean section because this may modify HBV transmission through excess blood exposure.

The primary meta-estimate – the OR of HBV transmission in Caesarean section compared with vaginal delivery – was calculated for all studies including 95% CIs. Meta-analyses using both fixed-effects (11) and a random-effects models were conducted (12). It was anticipated that there would be high level of heterogeneity among the studies; results were reported using the random-effects model. Binary outcomes are presented as OR with 95% CI. Pooled ORs and 95% CI were determined using a Mantel-Haenszel random-effects model. An OR of <1 favoured Caesarean section as having a preventive effect on HBV transmission while an OR of >1 indicated that Caesarean section was harmful and increased HBV transmission. The point estimate of the OR was considered to be statistically significant at the P<0.05 level if the 95% CI did not include the value 1.

Statistical between-study heterogeneity was assessed using the I2 test to measure the extent of inconsistency among the results and χ2 test, with statistical significance set at P<0.05. Publication bias was assessed using funnel plot (13). An asymmetric funnel plot suggests publication bias or a systematic difference between smaller and larger studies (‘small study effects’) or the use of an inappropriate effect measure. Publication bias was also evaluated by the Duval and Tweedie trim-and-fill method (14). To evaluate the impact of each individual study, sensitivity analyses using a one-study-removed method were performed. Temporal trends and secular changes were assessed with the cumulative analysis approach.

Because HBV transmission rates are directly influenced by prophylaxis with HBIG and vaccination, subgroup analyses were performed in an attempt to explain possible sources of heterogeneity and used the test for interaction (χ2 statistic) to estimate differences between groups. Unrestricted maximum likelihood random effects meta-regression was applied to percentage of HBIG administered as a continuous variable to evaluate for the impact of HBIG on HBV transmission rates. For all tests, a two-tailed P<0.05 was considered to be statistically significant. All analyses were performed in Comprehensive Meta Analysis Version 2.0 (Biostat, USA). The study is reported according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group reporting guidelines (15). All authors had access to the study data, and reviewed and approved the final manuscript.

RESULTS

Study selection

The search strategy identified 430 articles, of which 420 were excluded and 10 were included for analysis (Figure 1). Of the 10 studies included, eight were full-text articles (6,7,16–21) and two were major society meeting abstracts (9,22). One abstract (22) was found in EMBASE. The other abstract (9) was identified by searching the reference lists of the retrieved full-text articles.

Figure 1).

Figure 1)

Open in a new tab

Flow diagram of the study search and selection process. HCV Hepatitis C virus; pts Patients

Study characteristics are described in Table 1. Nine studies were retrospective cohort studies and one was a case-control study. The primary meta-estimate measured was the OR of HBV transmission from mothers to newborns among women who underwent Caesarean section (n=2352) compared with vaginal delivery (n=2739), yielding a total of 5091 newborns. The HBV transmission rate was 8% overall: 5% (116 of 2352) for mothers who underwent Caesarean section and 10% (283 of 2739) for those who underwent vaginal delivery. Three studies were conducted in HBeAg+ women exclusively, one study did not specify, and the remaining studies had mixed HBeAg+ and negative populations (range 25% to 55% HBeAg+). Prophylaxis rates with HBIG and HBV vaccination of infants varied across studies: three reported 100% prophylaxis with HBIG and vaccination, one did not mention prophylaxis rate, and the remaining studies reported a wide range (HBIG 51% to 76%, vaccination 1% to 100%). Four studies differentiated urgent from elective Caesarean section; only one study described whether instrumentation (forceps or suction) was used during delivery. Only four studies explicitly stated their exclusion criteria; all four excluded HIV, three excluded HCV coinfection and three excluded any form of recent HBV therapy (nucleos[t]ide analogues or interferon). Seven studies were conducted in China, two in Taiwan and one in India. According to the NOS, nine studies were high quality (scores between 6 and 9) and one study was low quality (score 4); however, only three of the studies controlled for potential confounders.

Table 1.

Characteristics of eligible studies

Author (reference), year (country) Study design Quality score Exclusion criteria Newborns by Caesarean/vaginal, n/n HbV+ newborns by Caesarean/vaginal, n/n HBeAg+/>106 copies/ml, % Given HBIG/ vaccine,% HBIG dosing Vaccine schedule Follow-up Caesarean section, % Forceps or vacuum, %
Elective Urgent
Lee et al (19), 1988 (China) Retrospective cohort 6/9 Not reported 62/385 6/96 100/– 76/100 50 IU ≤ 9 h ± at 1 month 2 weeks, 1, 2 months, 1 year 6 months Not reported Not reported Not reported
Wang et al (20), 2002 (China) Retrospective cohort 7/9 Not reported 117/184 11/15 Not reported All since 1997 100 IU 1, 2, 7 months 12 months Not reported Not reported 13
Zou et al (22), 2010 (China) Retrospective cohort/ abstract 7/9 Not reported 283/286 12/17 100/– 100/100 200 IU ≤ 12 h,2 weeks Delivery, 1, 6 months 12 months 33 17 Not reported
Dwivedi et al (17), 2011 (India) Retrospective cohort 7/9 Not reported 11/25 2/15 41/– Not reported Not reported Not reported At delivery 11 19 Not reported
Lu et al (9), 2012 (Taiwan) Retrospective cohort/abstract 8/9 Not reported 44/132 1/18 100 74/– Not reported Not reported Not stated Not reported Not reported Not reported
Chen et al (16), 2013 (China) Retrospective cohort 4/9 HIV, HCV, TB, Ig, nuc 98/73 21/14 35/29 100/100 200 IU ≤ 24 h ≤ 24 h, 1, 6 months At delivery Not reported Not reported Not reported
Guo et al (18), 2013 (China) Case control 7/9 Not reported 584/549 29/72 39/– 69/1 Not reported Not reported 24 h Not reported Not reported Not reported
Hu et al (6), 2013 (China) Retrospective cohort 7/9 HIV, HCV, nuc, threatened abortion 285/261 14/6 25/– 51/100 No dose, ≤24 h 3 doses total 1–7 years 52 0 Not reported
Pan et al (7), 2013 (China) Retrospective cohort 9/9 HIV, HCV, HDV, nuc/ IFN within 6 months 736/673 17/23 55/48 100/100 200 IU ≤ 6 h Delivery, 1, 6 months 7–12 months 35 17 Not reported
Wen et al (21), 2013 (Taiwan) Retrospective cohort 8/9 HIV 132/171 3/7 27/– 75*/100 100 IU ≤ 24 h Within 1 week, 1, 6 months 3 years Not reported Not reported Not reported
Open in a new tab
*

All hepatitis B e antigen-positive (HBeAg+) women received hepatitis B immune globulin (HBIG) and HBeAg-negative women were given the option to purchase HBIG. HCV Hepatitis C virus; Ig Immunoglobulin; HDV Hepatitis D virus; IFN Interferon; nuc Nucleos(t)ide analogue; TB Tuberculosis

Meta-analysis

Seven studies demonstrated decreased odds of HBV transmission, of which three were statistically significant, while three demonstrated increased odds of HBV transmission, but none were statistically significant (Figure 2). The overall meta-analysis demonstrated a statistically significant decrease in HBV vertical transmission with Caesarean section compared with vaginal delivery, with an OR of 0.62 (95% CI [0.40 to 0.978]; P=0.04). As expected, there was significant heterogeneity among the studies (Q test 25.58; P=0.003; I2=63%).

Figure 2).

Figure 2)

Open in a new tab

Meta-analysis of hepatitis B virus transmission risk with Caesarean section versus vaginal delivery

A one-study-removed analysis was generally consistent with the overall finding that Caesarean section was associated with a reduction in HBV transmission, although this resulted in having the upper limit of the 95% CI cross 1 (null) in seven of 10 cases (Wang et al [20] [OR 0.57 [95% CI 0.35 to 0.93], Chen et al [16] [OR 0.57 [95% CI 0.35 to 0.92] and Hu et al [6] [OR 0.55 [95% CI 0.36 to 0.83], forest plot not shown). A cumulative analysis demonstrated a persistent trend toward a protective effect of Caesarean section on HBV transmission as studies were added to the model over time, but this did not consistently reach statistical significance (data not shown). This finding may have been due to the publication of five studies in the same year. When including only high-quality studies (NOS ≥6) and excluding Chen et al (16) (NOS 4), Caesarean section still reduced HBV transmission (OR 0.57 [95% CI 0.35 to 0.92]). However, this effect was no longer significant when limiting the analysis to cohort studies (excluded Guo et al [18], which was a case control study) (OR 0.70 [95% CI 0.44 to 1.11]) or when considering only high-quality cohort studies (excluding both Chen et al [16] and Guo et al [18]) (OR 0.635 [95% CI 0.38 to 1.07]) (forest plots not shown).

A funnel plot was only mildly asymmetric, suggesting that smaller studies at the right margin of the plot, favouring an increase in HBV transmission with Caesarean section, may be missing (Figure 3). The Duval and Tweedie trim-and-fill method (14) did not add any studies, indicating that publication bias was not a significant factor.

Figure 3).

Figure 3)

Open in a new tab

Funnel plot of standard error according to hepatitis B virus transmission risk

Of the studies with <100% of HBIG administration in infants, the study by Hu et al (6) collected HBV prophylaxis administration data primarily using surveys one to seven years after childbirth, rendering the study vulnerable to recall bias. Additionally, the HBV transmission rate in the vaginal delivery group was disproportionately lower than expected (2%). While this may, in part, be due to the low HBeAg+ prevalence of 25%, the HBV transmission rate was still lower than Wen et al (21), which had a similar HBeAg+ prevalence of 27%, but a much higher HBV transmission rate of 4% in the vaginal delivery group, suggesting that the population in Hu et al (6) study may be fundamentally different from the other study populations. To better account for this persistent heterogeneity, a meta-regression was performed to evaluate a potential linear relationship between the percentage of patients administered HBIG and the log OR of HBV transmission. While there was no association in the initial model (P=0.78 [model not shown]), a subsequent meta-regression excluding Hu et al (6) (Figure 4) revealed a significant linear relationship, such that the log OR increased by 0.02 times for each percentage point increase in HBIG administered (P=0.005) This confirmed the expected clinical finding that HBV transmission decreased as HBIG use approached 100%, accounting for the underlying heterogeneity among studies.

Figure 4).

Figure 4)

Open in a new tab

Adjusted meta-regression of percent of women receiving hepatitis B immune globulin (HBIG) and log OR after removal of the study by Hu et al (6) (size of circles are proportional to study sample size)

A subgroup analysis stratified according to 100% HBV vaccination use found only a modest decrease in heterogeneity among studies that had 100% vaccination rates (Q test 9.86; P=0.08; I2= 49% [data not shown]). Further stratification within individual studies according to delivery type among women who received appropriate prophylaxis was not possible given the insufficient data. In three studies, data regarding rates of HBV transmission in HBeAg+ women, high risk for transmission, specified by delivery type were available. A separate analysis was performed that suggested a reduction in HBV transmission with Caesarean section but was not statistically significant (OR 0.71 [95% CI 0.47 to 1.08]; low heterogeneity, Q=0.18; P=0.92; I2=0%).

DISCUSSION

Using a random-effects pooled meta-analysis, we detected a statistically significant decrease in the overall odds of HBV transmission in women who underwent Caesarean section compared with vaginal delivery. In contrast, a majority of the individual studies had point estimates favouring a reduction in HBV transmission with Caesarean section, but were inconclusive because the 95% CI crossed 1. Our findings are consistent with the findings of meta-analyses before 2012: one was inconclusive and another found a benefit with Caesarean section (23,24). We were able to include six additional studies (3738 newborns) that have been published since 2012, making our meta-analysis the largest and most robust to date.

There was significant heterogeneity among studies, which was largely explained by varying rates of HBIG prophylaxis. In the adjusted meta-regression model, as HBIG use approached 100%, the protective benefit of Caesarean section appeared to decrease, confirming the importance of HBIG in preventing vertical transmission.

Despite demonstrating a benefit in HBV transmission, our findings should be interpreted within the context of the study limitations, particularly given the high heterogeneity and deficits in primary study quality. Although NOS scores were generally high, several of the studies were missing key study details, as depicted in the evidence table (Table 1), and only two studies controlled for confounders such as high viral levels and nucleos(t)ide use. Most studies were conducted in China, with a varying HBeAg+ prevalence and, therefore, may be less generalizable to other countries. Two of the more recent studies (9,22) were only available in abstract form, which significantly limits in-depth analysis. Follow-up periods in several studies spanned decades when HBV prophylaxis was not yet standard of care and many infants may not have received it; this may have elevated the risk for transmission in these studies. HBV transmission also differs in cases of elective compared with urgent Caesarean section for which there is potential for more bleeding and, thus, a greater opportunity for viral transmission. However, this level of detail was not available in most of the studies.

Interpretation of our study findings in the clinical setting is challenging because Caesarean section carries its own complex set of risks. HBIG administration and HBV vaccination should be the first-line measure based on established guidelines (1). All women diagnosed with HBV should be referred to a provider experienced in the management of chronic liver disease (8). Our meta-analysis demonstrated that Caesarean section may offer additional protection against vertical transmission of HBV from the mother to the newborn, but the exact degree of benefit remains uncertain and is heavily influenced by HBIG administration rates. Any protective benefit from Caesarean section most likely occurs in higher-risk mothers, namely those who are HBeAg+ or have persistently elevated DNA levels despite nucleos(t)ide therapy before delivery, and should be studied further. It would be difficult to perform an adequately powered study, which would require 475 women with high viremia who failed nucleos(t)ide therapy, for each delivery method (vaginal versus Caesarean) to have 80% power to detect a decrease in HBV transmission rates from 10% to 5%. Additionally, differences in HBV transmission rates among women undergoing elective versus urgent Caesarean section are still unknown and also require further investigation. Based on fair evidence, we cannot make formal recommendations for or against the use of Caesarean section to prevent transmission of HBV (Grade C). Ultimately, more definitive studies, such as large population-based cohort studies or planned meta-analyses that include 100% HBIG and vaccination use, are needed to confirm our findings before Caesarean section can be adopted in clinical practice as a preventive measure against vertical transmission of HBV.

Acknowledgments

The authors thank Michael Stoto PhD and Deanna Alexis Carere MA MS CGC CCGC (Harvard School of Public Health) for their meta-analysis guidance.

Footnotes

DISCLOSURES: PCA is an employee of Johnson & Johnson Medical, Brazil. The remaining authors have no financial disclosures or conflicts of interest to declare. This study was not funded.

REFERENCES

  • 1.Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–41. doi: 10.1016/j.cgh.2008.08.021. [DOI] [PubMed] [Google Scholar]
  • 2.Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10:452–9. doi: 10.1016/j.cgh.2011.10.041. [DOI] [PubMed] [Google Scholar]
  • 3.Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–21. doi: 10.1016/j.jhep.2011.02.032. [DOI] [PubMed] [Google Scholar]
  • 4.Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520–6. doi: 10.1016/j.cgh.2012.01.019. [DOI] [PubMed] [Google Scholar]
  • 5.Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev. 2005:CD005479. doi: 10.1002/14651858.CD005479. [DOI] [PubMed] [Google Scholar]
  • 6.Hu Y, Chen J, Wen J, et al. Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus. BMC Pregnancy Childbirth. 2013;13:119. doi: 10.1186/1471-2393-13-119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 2013;11:1349–55. doi: 10.1016/j.cgh.2013.04.026. [DOI] [PubMed] [Google Scholar]
  • 8.Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50:661–2. doi: 10.1002/hep.23190. [DOI] [PubMed] [Google Scholar]
  • 9.Lu SN, Wu CH, Ou CY, et al. Outcomes of combination of hepatitis B immunoglobuin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers. J Hepatol. 2012;56:S31–2. doi: 10.1016/j.bj.2021.11.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wells G, Shea B, O’Connell D, et al. The New Castle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. < wwwohrica/programs/clinical_epidemiology/oxford.asp> (Accessed August 16, 2013)
  • 11.Demets DL. Methods for combining randomized clinical trials: Strengths and limitations. Stat Med. 1987;6:341–50. doi: 10.1002/sim.4780060325. [DOI] [PubMed] [Google Scholar]
  • 12.DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 13.Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. doi: 10.1111/j.0006-341x.2000.00455.x. [DOI] [PubMed] [Google Scholar]
  • 15.Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12. doi: 10.1001/jama.283.15.2008. [DOI] [PubMed] [Google Scholar]
  • 16.Chen Y, Wang L, Xu Y, et al. Role of maternal viremia and placental infection in hepatitis B virus intrauterine transmission. Microbes Infect. 2013;15:409–15. doi: 10.1016/j.micinf.2013.02.008. [DOI] [PubMed] [Google Scholar]
  • 17.Dwivedi M, Misra SP, Misra V, et al. Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 2011;30:66–71. doi: 10.1007/s12664-011-0083-y. [DOI] [PubMed] [Google Scholar]
  • 18.Guo Z, Shi XH, Feng YL, et al. Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women. J Viral Hepatit. 2013;20:317–21. doi: 10.1111/jvh.12032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lee SD, Lo KJ, Tsai YT, et al. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus. Lancet. 1988;2:833–4. doi: 10.1016/s0140-6736(88)92792-4. [DOI] [PubMed] [Google Scholar]
  • 20.Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chinese Med J. 2002;115:1510–2. [PubMed] [Google Scholar]
  • 21.Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59:24–30. doi: 10.1016/j.jhep.2013.02.015. [DOI] [PubMed] [Google Scholar]
  • 22.Zou H, Chen Y, Duan Z, et al. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB) Hepatology. 2010;(Suppl):235A. (Abst) [Google Scholar]
  • 23.Wang HH, Wang ZP. [A Meta analysis: Mother to infant transmission of hepatitis B virus via different combined immunoprophylaxis delivery modes] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2010;44:221–3. [PubMed] [Google Scholar]
  • 24.Yang J, Zeng XM, Men YL, et al. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic review. Virol J. 2008;5:100. doi: 10.1186/1743-422X-5-100. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Journal of Gastroenterology & Hepatology are provided here courtesy of Wiley

RESOURCES